FATE THERAPEUTICS,INC. (NASDAQ:FATE) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.

On November23, 2016, Fate Therapeutics,Inc. (the Company) closed
a private placement (the Private Placement) in accordance with
the Securities Purchase Agreement (the Securities Purchase
Agreement) that the Company entered into on November21, 2016 with
a select group of institutional investors, including entities
affiliated with each of Redmile Group, LLC (Redmile), BVF
Partners L.P., EcoR1 Capital, LLC and Franklin Advisers, Inc.,
and other accredited investors, certain of whom are affiliated
with the directors and officers of the Company (the Purchasers).
to the Securities Purchase Agreement, Redmile purchased 2,819,549
shares of the Companys ClassA Convertible Preferred Stock, par
value $0.001 per share, at a price of $13.30 per share, and the
remaining Purchasers purchased an aggregate of 7,236,837 shares
of the Companys common stock, par value $0.001 per share, at a
price of $2.66 per share, for an aggregate purchase price of
approximately $57.0 million.

In connection with the closing of the Private Placement, the
Company filed a Certificate of Designation of Preferences, Rights
and Limitations of ClassA Convertible Preferred Stock with the
Secretary of State of Delaware on November22, 2016, to which the
Company designated 2,819,549 shares of its authorized and
unissued preferred stock as ClassA Convertible Preferred Stock.
The Certificate of Designation is filed hereto as Exhibit 3.1 and
incorporated by reference herein. A summary of the rights,
preferences and privileges of the ClassA Convertible Preferred
Stock is contained under Item 1.01 Entry into a Material
Definitive Agreement, in the Companys Form 8-K filed with the
Securities and Exchange Commission on November22, 2016, which is
incorporated by reference herein.

Item9.01Financial Statements and Exhibits

(d)Exhibits.

About FATE THERAPEUTICS, INC. (NASDAQ:FATE)

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company’s ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

FATE THERAPEUTICS, INC. (NASDAQ:FATE) Recent Trading Information

FATE THERAPEUTICS, INC. (NASDAQ:FATE) closed its last trading session down -0.09 at 3.09 with 310,834 shares trading hands.